Drug Trial Radar · NCT06317649
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
147
Planned (sponsor's estimate)
Start
Sep 27, 2024
Primary completion
May 15, 2029
Study completion May 15, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Mar 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Conditions
- Acute Myeloid Leukemia
Interventions
AzacitidineDrug
Given IV or SC
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow biopsy and aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy and aspiration
GilteritinibDrug
Given PO
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of measured residual disease (MRD) negative complete remission (CR)Time frame: Up to 4 cycles of treatment (1 cycle = 28 days)
Locations
229 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Active not recruiting
Kaiser Permanente Dublin
Dublin, California · Recruiting
Kaiser Permanente-Fremont
Fremont, California · Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California · Recruiting
Kaiser Permanente-Fresno
Fresno, California · Suspended
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente- Modesto MOB II
Modesto, California · Recruiting
Kaiser Permanente-Modesto
Modesto, California · Suspended
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Kaiser Permanente-Roseville
Roseville, California · Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Kaiser Permanente-South Sacramento
Sacramento, California · Recruiting
Kaiser Permanente-San Francisco
San Francisco, California · Recruiting
UCSF Medical Center-Parnassus
San Francisco, California · Recruiting
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California · Recruiting
Kaiser Permanente San Leandro
San Leandro, California · Recruiting
Mills Health Center
San Mateo, California · Active not recruiting
Kaiser San Rafael-Gallinas
San Rafael, California · Recruiting
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California · Recruiting
Kaiser Permanente-Santa Rosa
Santa Rosa, California · Recruiting
Kaiser Permanente-South San Francisco
South San Francisco, California · Recruiting
Kaiser Permanente-Vallejo
Vallejo, California · Recruiting
Kaiser Permanente-Walnut Creek
Walnut Creek, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Veterans Affairs Connecticut Healthcare System-West Haven Campus
West Haven, Connecticut · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Miami Cancer Institute
Miami, Florida · Recruiting
Phoebe Putney Memorial Hospital
Albany, Georgia · Recruiting
Augusta University Medical Center
Augusta, Georgia · Suspended
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii · Recruiting
Pali Momi Medical Center
‘Aiea, Hawaii · Recruiting
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii · Recruiting
Straub Clinic and Hospital
Honolulu, Hawaii · Recruiting
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii · Recruiting
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho · Recruiting
Showing 40 of 229 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.